ReviewCancer immunology, immunotherapy : CII2019
PLAC1: biology and potential application in cancer immunotherapy.
Review in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- siRNA-mediated silencing of placenta-specific protein 1 (PLAC1) alters CD4+, CD8+, and regulatory T cells in a murine colon cancer model.Scientific reports · 2026Article
- Fundamental and unique roles of PLAC1 in the regulation of rat and human trophoblast cell development.Development (Cambridge, England) · 2026Article
- Parallel and convergent dynamics in the evolution of primary breast and lung adenocarcinomas.Communications biology · 2025Article
- A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.Frontiers in immunology · 2025Article
- Identification of placenta-specific protein 1 (PLAC-1) expression on human PC-3 cell line-derived prostate cancer stem cells compared to the tumor parental cells.Discover oncology · 2024Article
- Placenta: an old organ with new functions.Frontiers in immunology · 2024Review
- Article
- Differential expression of PLAC1 and Netrin-1 in liver metastasis of colorectal cancer and its predictive value.BMC gastroenterology · 2023Article
- Protamine 1 as a secreted colorectal cancer-specific antigen facilitating G1/S phase transition under nutrient stress conditions.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Review
- Cancer Is Associated with the Emergence of Placenta-Reactive Autoantibodies.Biomedicines · 2023Article
- Human amniotic epithelial cells exert anti-cancer effects through secretion of immunomodulatory small extracellular vesicles (sEV).Cancer cell international · 2022Article
- The prognostic value of homeobox A9 (HOXA9) methylation in solid tumors: a systematic review and meta-analysis.Translational cancer research · 2021Article
- Placenta-specific protein 1 enhances liver metastatic potential and is associated with the PI3K/AKT/NF-κB signaling pathway in colorectal cancer.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2021Article
- Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens.Genes & cancer · 2021Article
- Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.Oncoimmunology · 2020Article
- PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation.Oncotarget · 2020Article
- Optimization of Expression and Purification of Recombinant Mouse plac1.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
The emergence of immunotherapy has revolutionized medical oncology with unprecedented advances in cancer treatment over the past two decades. However, a major obstacle in cancer immunotherapy is identifying appropriate tumor-specific antigens to make targeted therapy achievable with fewer normal cells being impaired. The similarity between placentation and tumor development and growth has inspired many investigators to discover antigens for effective immunotherapy of cancers. Placenta-specific 1 (PLAC1) is one of the recently discovered placental antigens with limited normal tissue expression and fundamental roles in placental function and development. There is a growing body of evidence showing that PLAC1 is frequently activated in a wide variety of cancer types and promotes cancer progression. Based on the restricted expression of PLAC1 in testis, placenta and a wide variety of cancers, we have designated this molecule with new terminology, cancer-testis-placenta (CTP) antigen, a feature that PLAC1 shares with many other cancer testis antigens. Recent reports from our lab provide compelling evidence on the preferential expression of PLAC1 in prostate cancer and its potential utility in prostate cancer immunotherapy. PLAC1 may be regarded as a potential CTP antigen for targeted cancer immunotherapy based on the available data on its promoting function in cancer development and also its expression in cancers of different histological origin. In this review, we will summarize current data on PLAC1 with emphasis on its association with cancer development and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.